A Linkage and Association Study in Pulmonary Fibrosis (GWAS)

This study is currently recruiting participants.
Verified February 2010 by National Jewish Health
Sponsor:
Collaborators:
University of Colorado, Denver
Vanderbilt University
Landspitali University Hospital
Information provided by (Responsible Party):
National Jewish Health
ClinicalTrials.gov Identifier:
NCT01088217
First received: March 15, 2010
Last updated: March 14, 2012
Last verified: February 2010
  Purpose

The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis.


Condition
Idiopathic Pulmonary Fibrosis
Familial Pulmonary Fibrosis
Idiopathic Interstitial Pneumonia
Familial Interstitial Pneumonia

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Cross-Sectional
Official Title: GWAS in Fibrosing Interstitial Lung Disease

Resource links provided by NLM:


Further study details as provided by National Jewish Health:

Biospecimen Retention:   Samples With DNA

whole blood, serum, plasma, lung tissue, DNA, RNA


Estimated Enrollment: 8000
Study Start Date: July 2008
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Detailed Description:

Familial Pulmonary Fibrosis (FPF) is a sub-category of the idiopathic interstitial pneumonias (IIPs). IIPs are progressive lung conditions, with limited treatment options and unknown etiology. Though the IIPs have been associated with both genetic risk factors and environmental exposures, the molecular mechanism underlying disease progression remain poorly understood. This investigation seeks to identify a group of genetic loci that play a role in the development of familial interstitial pneumonia (FIP) or FPF, where 2 or more cases of IIP are seen within a family.

  Eligibility

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Families with two or more individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)

Criteria

Inclusion Criteria:

  • Two or more family members with a clinical diagnosis of Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)
  • Additional family members may be eligible to participate if two family members are suspected of or diagnosed as having Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Interstitial Pneumonia (IIP)

Exclusion Criteria:

  • Individuals whose pulmonary fibrosis is due to a known cause rather than idiopathic
  • Individuals whose pulmonary fibrosis is due to a broader genetic syndrome
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01088217

Contacts
Contact: Janet Talbert, MS, CGC 800-423-8891 ext 1022 talbertj@njhealth.org

Locations
United States, Colorado
National Jewish Health and University of Colorado Denver Recruiting
Denver, Colorado, United States, 80206
Contact: Janet Talbert, MS, CGC     800-423-8891 ext 1022     talbertj@njhealth.org    
Principal Investigator: David A. Schwartz, MD            
Sub-Investigator: Kevin K. Brown, MD            
Sub-Investigator: Gregory P. Cosgrove, MD            
Sub-Investigator: Marvin I. Schwarz, MD            
Sub-Investigator: Tasha Fingerlin, PhD            
Sub-Investigator: Steve Groshong, MD, PhD            
Sub-Investigator: David Lynch, MD            
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37232
Contact: Cheryl Markin, MT     888-898-1550     cheryl.markin@vanderbilt.edu    
Principal Investigator: James E. Loyd, MD            
Iceland
Landspitali University Hospital Recruiting
Reykjavik, Iceland
Principal Investigator: Gunnar Gudmundsson, MD            
Sponsors and Collaborators
National Jewish Health
University of Colorado, Denver
Vanderbilt University
Landspitali University Hospital
Investigators
Principal Investigator: David A. Schwartz, MD University of Colorado Denver; National Jewish Health
  More Information

Additional Information:
No publications provided

Responsible Party: National Jewish Health
ClinicalTrials.gov Identifier: NCT01088217     History of Changes
Other Study ID Numbers: 1RO1HL097163
Study First Received: March 15, 2010
Last Updated: March 14, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by National Jewish Health:
Idiopathic Pulmonary Fibrosis
Familial Pulmonary Fibrosis
Idiopathic Interstitial Pneumonia
Familial Interstitial Pneumonia
Pulmonary Fibrosis

Additional relevant MeSH terms:
Fibrosis
Pneumonia
Pulmonary Fibrosis
Lung Diseases, Interstitial
Idiopathic Interstitial Pneumonias
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on May 19, 2013